ReviewCurrent drug targets2010
Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy.
Review in Current drug targets, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 202 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)
A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Who cites it
202 citing papers in PubMed, 4 syntheses or guidelines pooled it, 452 citations in OpenAlex.
- Update Prognostic Potency of Vascular Endothelial Growth Factor-A in the Acute Lymphoblastic Leukemia Landscape: A Meta-Analysis.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- Vascular Endothelial Growth Factor and the Pathogenesis of Intracranial Aneurysms: A Systematic Review on the Missing Link in a Complex Pathway.Journal of the American Heart Association · 2024Pooled it
- Pooled it
- Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies.Journal of cancer research and clinical oncology · 2011Pooled it
- Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.Cancer research and treatment · 2024Trial
- Angiogenic cytokines and their influence on circulating tumour cells in sera of patients with the primary diagnosis of breast cancer before treatment.BMC cancer · 2016Trial
- Advances in applications of siRNA in cancer therapy: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Liposomal honokiol attenuates dimethylhydrazine-induced colon carcinogenesis in rats through modulation of oxidative stress, inflammation, apoptosis, autophagy, and lipid metabolism pathways.Medical oncology (Northwood, London, England) · 2026Article
- Prognostic significance of serum iron panel in breast carcinoma: correlation with histopathological grading and molecular immunophenotypes.Discover oncology · 2026Review
- MicroRNA-VEGF axis in gastric cancer: a novel therapeutic frontier.Discover oncology · 2026Review
- Esophageal perforation in a patient with lung cancer after administration of bevacizumab combined with radiotherapy and chemotherapy: A case report.Oncology letters · 2025Article
- Mechanisms of action of retinal microglia in diabetic retinopathy (Review).International journal of molecular medicine · 2025Review
- Progress in Molecular Imprinting-From Inhibition of Enzymatic Activity to Regulation of Cellular Pathways.Medicinal research reviews · 2025Review
- Computational analysis of miRNA mediated KDR gene regulation and natural VEGFR2 inhibitors from Persicaria hydropiper in hepatocellular carcinoma.Scientific reports · 2025Article
- The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents.Pharmacology research & perspectives · 2025Article
- Polymorphisms inBiomedicines · 2025Review
- Association between VEGF gene polymorphisms and breast cancer risk.Biochemistry and biophysics reports · 2025Article
- Beyond pelvic pathology: retinal microvascular rarefaction as a systemic marker in endometriosis.BMC women's health · 2025Article
- VEGFA (rs1570360, rs699947, rs3025033, rs2146323, rs3024997) genotypes in patients with laryngeal squamous cell carcinoma.BMC cancer · 2025Article
- Role of the tumor microenvironment in cancer therapy: unveiling new targets to overcome drug resistance.Medical oncology (Northwood, London, England) · 2025Review
142 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
New blood vessel formation (angiogenesis) is fundamental to tumor growth, invasion, and metastatic dissemination. The vascular endothelial growth factor (VEGF) signaling pathway plays pivotal roles in regulating tumor angiogenesis. VEGF as a therapeutic target has been validated in various types of human cancers. Different agents including antibodies, aptamers, peptides, and small molecules have been extensively investigated to block VEGF and its pro-angiogenic functions. Some of these agents have been approved by FDA and some are currently in clinical trials. Combination therapies are also being pursued for better tumor control. By providing comprehensive real-time information, molecular imaging of VEGF pathway may accelerate the drug development process. Moreover, the imaging will be of great help for patient stratification and therapeutic effect monitoring, which will promote effective personalized molecular cancer therapy. This review summarizes the current status of tumor therapeutic agents targeting to VEGF and the applications of VEGF related molecular imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.